drugset / Trial / NCT00518245

Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

NCT00518245 ↗

Phase 4 Terminated 11 enrolled Canadian Heart Research Centre Sanofi · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether enoxaparin (an anticoagulant) is effective in the treatment of patients presenting to the emergency room with chest pain and no electrocardiogram or bloodwork evidence of a heart attack, but with other high risk clinical features

Timeline

Start
2007-08
Primary completion
2009-03
Completion
2009-08

Outcome

Outcome not reported

Stopped (Enrollment): “Low rate of patient recruitment. Cannot achieve sample size.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 1 mg/kg Subcutaneous